Molecular Prognostic Factors in Cytogenetically Normal Acute Myeloid Leukemia

Overview

Journal Expert Rev Hematol

Specialty Hematology

Date 2012 Nov 14

PMID 23146058

Citations 18

Authors

Alison Walker

Guido Marcucci

Affiliations

Soon will be listed here.

Abstract

Chromosomal abnormalities are detected in 50-60% of patients with acute myeloid leukemia (AML) and are important predictors of prognosis and risk of relapse. The remaining patients, those with cytogenetically normal AML, are a seemingly homogeneous group that in fact consists of subsets of patients with distinct clinical outcomes. This heterogeneity is likely related to acquired gene mutations, as well as altered miRNA and gene-expression profiles, which occur within the group. The identification of recurrent molecular abnormalities has improved prognostication and provided insight into mechanisms of leukemogenesis for patients with cytogenetically normal AML, as well as led to the discovery of novel therapeutic targets. As the number of mutations continues to expand, bioinformatic algorithms that allow for integration of multiple markers will be necessary to provide optimal care for patients with this disease.

Citing Articles

Deciphering cell states and the cellular ecosystem to improve risk stratification in acute myeloid leukemia.

Zhang Z, Tang R, Zhu M, Zhu Z, Zhu J, Li H Brief Bioinform. 2025; 26(1).

PMID: 39865982 PMC: 11770069. DOI: 10.1093/bib/bbaf028.

Immunotherapy-relevance of a candidate prognostic score for Acute Myeloid Leukemia.

Pan Y, Zeng W, Nie X, Chen H, Xie C, Guo S Heliyon. 2024; 10(11):e32154.

PMID: 38961904 PMC: 11219318. DOI: 10.1016/j.heliyon.2024.e32154.

Altered expression of imprinted genes in patients with cytogenetically normal‑acute myeloid leukemia: Implications for leukemogenesis and survival outcomes.

Yang M, Hsu C, Lin P, Yang C, Hu M, Chen I Mol Clin Oncol. 2023; 19(6):94.

PMID: 37920417 PMC: 10619196. DOI: 10.3892/mco.2023.2690.

Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers.

Sahajpal N, Mondal A, Singh H, Vashisht A, Ananth S, Saul D Cancers (Basel). 2023; 15(12).

PMID: 37370824 PMC: 10296552. DOI: 10.3390/cancers15123214.

Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Lee Y, Lim H, Park J, Kim H, Kang M, Cho Y Ann Lab Med. 2022; 42(5):585-589.

PMID: 35470276 PMC: 9057826. DOI: 10.3343/alm.2022.42.5.585.

References

Langer C, Radmacher M, Ruppert A, Whitman S, Paschka P, Mrozek K . High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B.... Blood. 2008; 111(11):5371-9. PMC: 2396728. DOI: 10.1182/blood-2007-11-124958. View

Thol F, Friesen I, Damm F, Yun H, Weissinger E, Krauter J . Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(18):2499-506. DOI: 10.1200/JCO.2010.33.4938. View

Byrd J, Mrozek K, Dodge R, Carroll A, Edwards C, Arthur D . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13):4325-36. DOI: 10.1182/blood-2002-03-0772. View

Schlenk R, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F . Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2008; 94(1):54-60. PMC: 2625424. DOI: 10.3324/haematol.13378. View

Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J . Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009; 23(11):2183-6. DOI: 10.1038/leu.2009.141. View

Whitman S, Liu S, Vukosavljevic T, Rush L, Yu L, Liu C . The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 2005; 106(1):345-52. PMC: 1895129. DOI: 10.1182/blood-2005-01-0204. View

Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi Y . Array-based genomic resequencing of human leukemia. Oncogene. 2010; 29(25):3723-31. DOI: 10.1038/onc.2010.117. View

Oikawa T . ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 2004; 95(8):626-33. PMC: 11159856. DOI: 10.1111/j.1349-7006.2004.tb03320.x. View

Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B . High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006; 108(12):3898-905. DOI: 10.1182/blood-2006-04-014845. View

10.

Langer C, Marcucci G, Holland K, Radmacher M, Maharry K, Paschka P . Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009; 27(19):3198-204. PMC: 2716941. DOI: 10.1200/JCO.2008.20.6110. View

11.

Hohenstein P, Hastie N . The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006; 15 Spec No 2:R196-201. DOI: 10.1093/hmg/ddl196. View

12.

Frohling S, Schlenk R, Stolze I, Bihlmayr J, Benner A, Kreitmeier S . CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22(4):624-33. DOI: 10.1200/JCO.2004.06.060. View

13.

Becker H, Marcucci G, Maharry K, Radmacher M, Mrozek K, Margeson D . Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2009; 28(4):596-604. PMC: 2815994. DOI: 10.1200/JCO.2009.25.1496. View

14.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Gohring G . Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2009; 28(4):578-85. DOI: 10.1200/JCO.2009.23.0342. View

15.

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

16.

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M . Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106(12):3733-9. DOI: 10.1182/blood-2005-06-2248. View

17.

Rockova V, Abbas S, Wouters B, Erpelinck C, Beverloo H, Delwel R . Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011; 118(4):1069-76. DOI: 10.1182/blood-2011-02-334748. View

18.

Metzeler K, Maharry K, Radmacher M, Mrozek K, Margeson D, Becker H . TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10):1373-81. PMC: 3084003. DOI: 10.1200/JCO.2010.32.7742. View

19.

Taskesen E, Bullinger L, Corbacioglu A, Sanders M, Erpelinck C, Wouters B . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2010; 117(8):2469-75. DOI: 10.1182/blood-2010-09-307280. View

20.

Metzeler K, Walker A, Geyer S, Garzon R, Klisovic R, Bloomfield C . DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2011; 26(5):1106-7. PMC: 3696987. DOI: 10.1038/leu.2011.342. View